scholarly journals Cost-Effectiveness of Statin Therapy For Secondary Prevention Among Patients With Coronary Artery Disease With Baseline LDL-C Level Of 70–100 Mg/DL In Taiwan

2018 ◽  
Vol 21 ◽  
pp. S30
Author(s):  
F Lin ◽  
W Shau ◽  
Y Wen ◽  
JZ Li ◽  
SS Fung ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Secondary Prevention ◽  
Statin Therapy ◽  
Artery Disease

scholarly journals Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70–100 mg/dL in Taiwan

2020 ◽  
Vol 119 (5) ◽  
pp. 907-916 ◽  
Author(s):  
Fang-Ju Lin ◽  
Kou-Gi Shyu ◽  
I-Chang Hsieh ◽  
Wayne Huey-Herng Sheu ◽  
Shih-Te Tu ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Secondary Prevention ◽  
Statin Therapy ◽  
Artery Disease

scholarly journals Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease

Circulation ◽  
2007 ◽  
Vol 115 (18) ◽  
pp. 2398-2409 ◽  
Author(s):  
Paul S. Chan ◽  
Brahmajee K. Nallamothu ◽  
Hitinder S. Gurm ◽  
Rodney A. Hayward ◽  
Sandeep Vijan
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
High Risk ◽  
Statin Therapy ◽  
High Dose ◽  
Incremental Benefit ◽  
High Risk Patients ◽  
Risk Patients ◽  
Artery Disease

scholarly journals Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e044054
Author(s):  
Victoria McCreanor ◽  
Alexandra Nowbar ◽  
Christopher Rajkumar ◽  
Adrian G Barnett ◽  
Darrel Francis ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Coronary Intervention ◽  
Single Vessel ◽  
Vessel Coronary Artery Disease ◽  
Effectiveness Analysis ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
Vessel Coronary Artery

ObjectiveTo evaluate the cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina despite anti-anginal therapy.DesignA cost-effectiveness analysis comparing PCI with placebo. A Markov model was used to measure incremental cost-effectiveness, in cost per quality-adjusted life-years (QALYs) gained, over 12 months. Health utility weights were estimated using responses to the EuroQol 5-level questionnaire, from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial and UK preference weights. Costs of procedures and follow-up consultations were derived from Healthcare Resource Group reference costs and drug costs from the National Health Service (NHS) drug tariff. Probabilistic sensitivity analysis was undertaken to test the robustness of results to parameter uncertainty. Scenario analyses were performed to test the effect on results of reduced pharmaceutical costs in patients undergoing PCI, and the effect of patients crossing over from placebo to PCI due to refractory angina within 12 months.SettingFive UK NHS hospitals.Participants200 adult patients with stable angina and angiographically severe single-vessel coronary artery disease on anti-anginal therapy.InterventionsAt recruitment, patients received 6 weeks of optimisation of medical therapy for angina after which they were randomised to PCI or a placebo procedure.Outcome measuresIncremental cost-effectiveness ratio (ICER) expressed as cost (in £) per QALY gained for PCI compared with placebo.ResultsThe estimated ICER is £90 218/QALY gained when using PCI compared with placebo in patients receiving medical treatment for angina due to single-vessel coronary artery disease. Results were robust under sensitivity analyses.ConclusionsThe ICER for PCI compared with placebo, in patients with single-vessel coronary artery disease and angina on anti-anginal medication, exceeds the threshold of £30 000 used by the National Institute of Health and Care Excellence when undertaking health technology assessment for the NHS context.Trial registration: The ORBITA study is registered with ClinicalTrials.gov, number NCT02062593.

scholarly journals The scientific basis for secondary prevention of coronary artery disease: recent contributions from the Netherlands

2020 ◽  
Vol 28 (S1) ◽  
pp. 136-140
Author(s):  
H. T. Jørstad ◽  
M. Snaterse ◽  
N. ter Hoeve ◽  
M. Sunamura ◽  
R. Brouwers ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
The Netherlands ◽  
Secondary Prevention ◽  
Scientific Basis ◽  
Artery Disease

Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease

2013 ◽  
Vol 28 (1) ◽  
pp. 53-59 ◽  
Author(s):  
Kentaro Toyama ◽  
Toshihiko Nishioka ◽  
Ami Isshiki ◽  
Toshiyuki Ando ◽  
Yoshiro Inoue ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Endothelial Dysfunction ◽  
Eicosapentaenoic Acid ◽  
Statin Therapy ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document